Data Bytes: record fund for Longitude follows rush of deals, IPOs

On the back of seven liquidity events in the past four months, Longitude Capital has closed its largest fund to date at $585 million.

Managing Director Patrick Enright told BioCentury Longitude Venture Partners IV will stick close to firm’s existing strategy and invest in about 25 companies, with two thirds allocated to biotech and the remainder to medtech. Within therapeutics, the fund will focus on cancer, orphan diseases and neurodegeneration and other conditions associated with aging...